# Haleon PLC (HLN.L) fundamentals

Data as of 2026-11-04. LSE, United Kingdom. Sector: Healthcare / Pharmaceuticals. Price 324p, market value 28.4 billionp.

## Valuation
- **P/E (trailing): 18.0×**. Haleon PLC trades at 18.0× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 14.5×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 2.6×**. Each dollar of revenue is priced at 2.6×.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.5×**. Enterprise value is 12.5× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 7.8%**. Free cash flow equals 7.8% of the market value. Above 5% is generally attractive.
- **Earnings yield: 5.6%**. The inverse of the P/E: 5.6% of the price is earned each year.

## Profitability
- **Gross margin: 64.2%**. Haleon PLC keeps 64.2% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 21.9%**. 21.9% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 15.1%**. 15.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.1%**. 10.1% on shareholders' equity is solid.
- **Return on invested capital: 7.9%**. Return on all capital, debt included, is 7.9%.
- **Return on assets: 5.1%**. Each dollar of assets produces 5.1% of profit.

## Growth
- **Revenue growth (1 yr): -1.8%** (3-yr 0.5%/yr). Revenue fell 1.8% over the last year.
- **Free-cash-flow growth (3 yr): 8.6%/yr**. Free cash flow has compounded at 8.6% a year over three years.

## Financial health
- **Debt to equity: 0.52**. Debt is 0.52 times equity, moderate leverage.
- **Net debt / EBITDA: 2.6×**. It would take 2.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 7.0×**. Operating profit covers interest 7.0× over, a safe margin.
- **Current ratio: 0.92** (quick 0.71). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 2.34**. A Z-score of 2.34 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 2.26%** (0p per share, trailing). Haleon PLC yields 2.26%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 37%** (28% of free cash flow). 37% of earnings goes out as dividends, leaving room to keep raising it.
- **Shareholder yield: 4.6%**. Dividends plus net buybacks return 4.6% of the market value a year.

## Price and momentum
- **Total return (1 yr): -8.9%** (YTD -14.8%, 3-mo -12.1%). The shares are down 8.9% over twelve months including dividends.
- **From 52-week high: -25.4%** (4.2% above the low). Trading 25% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 30**. An RSI of 30 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 0.58** (volatility 27%). Beta of 0.58 against the FTSE All-Share: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HLN.L · Page: https://foliofundamentals.com/stocks/hln.l

Not investment advice.